Migraine And Headache
The investigators believe that ketamine may still hold some benefits for treatment of acute headache in the emergency department.
The efficacy of oral versus intranasal delivery of sumatriptan on migraine-related nausea was evaluated in the COMPASS study.
Pediatric patients with NDPH experience more sleep disturbances than those with migraine or tension-type headaches.
Despite mounting evidence suggesting the contrary, the debate on the potential benefits of patent foramen ovale closure for migraine is still ongoing.
Over half of all individuals included in this study reported headache attacks occurring at specific time periods throughout the day.
In the emergency department, it was found that IV prochlorperazine plus diphenhydramine was better than IV hydromorphone for treating migraine pain.
The FDA has accepted a Biologics License Application for fremanezumab to prevent migraine.
Clinically significant decreases were noted for concomitant medications and oral morphine equivalency.
The FDA has posted a discontinuation notice for Zecuity.
For treating acute migraine, IV hydromorphone is less effective than IV prochlorperazine plus diphenhydramine.
In patients with migraine, quality of life can be improved with a multidisciplinary medical approach to treating headaches.
Ketamine effectively treats many painful conditions and has shown promise in patients with chronic migraine and other intractable headaches.
Intranasal administration of sumatriptan allows for dual absorption in the nasal cavity and the intestines.
Many HIV-positive patients experience frequent headaches that impact their quality of life.
The 2 treatments for cluster headache with Level A recommendations are either not readily accessible via public or private insurance or are not recommended in a large subset of patients with cardiovascular disease.
A case series described a new subtype of chronic daily headache that may be associated with increased CSF pressure.
Despite a recent study concluding that oxygen therapy for cluster headache is not cost-prohibitive, many private payers and Medicare and Medicaid do not cover the effective therapy. Matthew Robbins, MD, Stewart Tepper, MD, and others weigh in on the controversial decision.
Patients with migraine who received nasal sumatriptan experienced faster relief of pain and disability associated with migraine.
Painful signs and symptoms frequently occur prior to cluster headache attacks.
Monthly injections of 120 mg or 240 mg galcanezumab helped reduce number of migraine days.
Girls with recurrent headaches in childhood should be monitored closely for the development of headache or migraine in adolescence.
Bridge therapy with IV methylprednisone and diazepam reduced headache pain.
While several theories have evolved over the years, none have unequivocally provided robust evidence to fully explain the clinical spectrum of migraine.
Opioids are prescribed more than triptan medications for headache and migraine.
The current costs of medical grade oxygen for treating cluster headache are not "prohibitively expensive."
The FDA's clearance was based on review of the post-marketing ESPOUSE Study that included 132 patients with migraine.
Several CIM methods bring value and their integration into a headache management plan in the clinical setting empowers patients' healing process.
There are nearly as many migraine patients receiving opioids as there are patients receiving level A abortive medications.
Future predictive models may need to include other migraine risk factors to enhance predictive accuracy.
The study group concluded that the current recommendation for CSF pressure reduction therapy to relieve headaches attributed to IIH should be removed from the International Classification of Headache Disorders 3b criteria.
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Prochlorperazine More Effective Than Ketamine for Headache Relief in the Emergency Department
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- Cognitive Impairment in Multi-System Atrophy: Is It Time to Update Diagnostic Criteria?
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- NBT System Gets FDA Clearance for Depression Treatment
- Coffee Consumption May Decrease Stroke Risk
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug
- Nusinersen Improves Motor Function, Survival in Infants With Spinal Muscular Atrophy
- Noninvasive Brain Stimulation System Approved for Depression
- Hypertension Guidelines Updated by AHA/ACA
- Bone Mineral Density Associated With Intracranial Aneurysm Presence, Size